サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798907

HER2乳がん検査の世界市場

HER2 Breast Cancer Tests

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
HER2乳がん検査の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

HER2乳がん検査の世界市場は2030年までに5億2,950万米ドルに達する見込み

2024年に3億9,440万米ドルと推定されるHER2乳がん検査の世界市場は、2030年には5億2,950万米ドルに達し、分析期間2024-2030年のCAGRは5.0%で成長すると予測されます。本レポートで分析したセグメントの1つである免疫組織化学検査は、CAGR 4.0%を記録し、分析期間終了時には3億3,130万米ドルに達すると予測されます。蛍光/発色In-Situハイブリダイゼーション検査分野の成長率は、分析期間中CAGR 6.8%と推定されます。

米国市場は1億740万米ドルと推定、中国はCAGR 7.8％で成長予測

米国のHER2乳がん検査市場は、2024年に1億740万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億410万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.0％と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界のHER2乳がん検査市場- 主要動向と促進要因のまとめ

なぜHER2乳がん検査は現代の腫瘍学に不可欠なのか？

HER2（Human Epidermal Growth Factor Receptor 2）乳がん検査は、乳がん組織におけるHER2遺伝子の過剰発現または増幅を判定するために使用される診断手順です。HER2陽性のがんは一般的に増殖が速く、標的治療に対する反応も異なるため、これらの検査は治療方針を決定する上で極めて重要です。正確な同定により、トラスツズマブやペルツズマブなど、HER2活性を特異的に阻害し、生存予後を改善する治療法の選択が可能となります。

検査は通常、生検または外科的組織サンプルを用いた免疫組織化学（IHC）またはin situハイブリダイゼーション（ISH）技術を用いて行われます。近年、診断精度を向上させるために、高度なアッセイ法、デジタル病理学的ソリューション、コンパニオン診断薬が登場しています。HER2検査は現在、腫瘍センターにおける乳がん診断のルーチンの一部となっており、高品質で信頼性の高い診断プラットフォームに対する需要の高まりに寄与しています。

どのような診断イノベーションが検査の精度と普及に影響を与えているか？

技術の進歩により、HER2検査の感度、再現性、解釈可能性は向上しています。IHC検査は、強化された抗体、自動染色システム、標準化されたスコアリング・アルゴリズムによって進化してきました。デュアルプローブISH検査は曖昧な症例に確証を与え、境界領域のHER2発現を解決するのに役立ちます。蛍光ISH（FISH）および発色ISH（CISH）は、細胞レベルでの遺伝子増幅の確認に広く用いられています。

新しいプラットフォームは、診断ワークフローを強化するために、デジタル画像、AI支援病理学、マルチプレックス検査機能を統合しています。HER2アッセイの中には、複数のバイオマーカーを同時に評価する広範なゲノムプロファイリング検査の一部として開発されているものもあります。特にHER2を標的とした治療が胃がんや大腸がんなどの他のがん種に拡大するにつれて、標的薬と共同開発されたコンパニオン診断検査も人気を集めています。

検査量はどこで増加し、どの施設が普及を牽引しているか？

乳がん罹患率の増加および腫瘍学における個別化医療の採用の拡大により、検査量は世界的に増加しています。病院、がん専門センター、基準検査室が主要な検査施設です。高所得国では、HER2検査は乳がん検診の標準的な検査項目であり、中所得地域では、病理学的インフラストラクチャーと治療アクセスの改善により、検査への関心が高まっています。

北米と欧州は、診断ガイドラインと償還制度が確立された成熟市場です。アジア太平洋地域は、乳がんに対する意識の高まり、標的治療へのアクセスの拡大、がん診断薬を支援する政府の取り組みなどにより、急成長を遂げています。官民パートナーシップや全国的ながん検診プログラムの開発は、検査の普及をさらに加速させています。

HER2乳がん検査市場の成長の原動力は？

HER2乳がん検査市場の成長は、世界の乳がん罹患率の上昇、HER2標的治療薬の使用増加、診断精度の継続的向上など、いくつかの要因によってもたらされます。染色試薬、自動化システム、AIを搭載した病理検査ツールの進歩により、HER2検査の精度と拡張性が高まっています。

がん専門病院、病理検査室、HER2標的新薬のコンパニオン診断における最終用途の拡大が市場の関連性を高めています。乳がん以外の腫瘍型におけるHER2検査の規制承認とマルチプレックスバイオマーカーパネルの採用増加により、応用範囲が広がっています。精密医療が腫瘍治療の中心になるにつれて、信頼性の高い高スループットのHER2検査ソリューションに対する需要は着実に拡大すると予想されます。

セグメント

検査タイプ（免疫組織化学検査、蛍光/発色In-Situハイブリダイゼーション検査）;エンドユーザー（病院エンドユーザー、診断ラボエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter（Danaher）
  • Becton, Dickinson and Company（BD）
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems（Danaher）
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology（Sysmex）
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics（F. Hoffmann-La Roche）
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics/Biocare Medical
  • Applied Spectral Imaging

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38902

Global HER2 Breast Cancer Tests Market to Reach US$529.5 Million by 2030

The global market for HER2 Breast Cancer Tests estimated at US$394.4 Million in the year 2024, is expected to reach US$529.5 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunohistochemistry Test, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$331.3 Million by the end of the analysis period. Growth in the Fluorescence / Chromogenic In-Situ Hybridization Test segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.4 Million While China is Forecast to Grow at 7.8% CAGR

The HER2 Breast Cancer Tests market in the U.S. is estimated at US$107.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global HER2 Breast Cancer Tests Market - Key Trends & Drivers Summarized

Why Are HER2 Breast Cancer Tests Essential in Modern Oncology?

HER2 (Human Epidermal Growth Factor Receptor 2) breast cancer tests are diagnostic procedures used to determine the overexpression or amplification of the HER2 gene in breast cancer tissue. These tests are critical in guiding treatment decisions, as HER2-positive cancers typically grow faster and respond differently to targeted therapies. Accurate identification allows for the selection of therapies such as trastuzumab or pertuzumab, which specifically inhibit HER2 activity and improve survival outcomes.

Testing is typically performed using immunohistochemistry (IHC) or in situ hybridization (ISH) techniques on biopsy or surgical tissue samples. In recent years, advanced assays, digital pathology solutions, and companion diagnostics have emerged to improve diagnostic precision. HER2 testing is now a routine part of breast cancer diagnosis in oncology centers, contributing to the growing demand for high-quality and reliable diagnostic platforms.

What Diagnostic Innovations Are Influencing Test Accuracy and Adoption?

Technological advancements have improved HER2 test sensitivity, reproducibility, and interpretability. IHC tests have evolved with enhanced antibodies, automated staining systems, and standardized scoring algorithms. Dual-probe ISH tests provide confirmation in ambiguous cases, helping resolve borderline HER2 expressions. Fluorescence ISH (FISH) and chromogenic ISH (CISH) remain widely used for confirming gene amplification at the cellular level.

Emerging platforms are integrating digital imaging, AI-assisted pathology, and multiplex testing capabilities to enhance diagnostic workflows. Some HER2 assays are now being developed as part of broader genomic profiling tests that assess multiple biomarkers simultaneously. Companion diagnostic tests co-developed with targeted drugs are also gaining traction, especially as HER2-targeted treatments expand into other tumor types like gastric and colorectal cancers.

Where Is Testing Volume Increasing, and Which Institutions Are Driving Uptake?

Testing volumes are rising globally due to increasing breast cancer incidence and the growing adoption of personalized medicine in oncology. Hospitals, cancer specialty centers, and reference laboratories are key testing sites. In high-income countries, HER2 testing is a standard part of breast cancer workups, while in middle-income regions, uptake is increasing with improvements in pathology infrastructure and treatment access.

North America and Europe are mature markets with well-established diagnostic guidelines and reimbursement systems. Asia Pacific is witnessing rapid growth due to rising breast cancer awareness, expanding access to targeted therapies, and government initiatives supporting oncology diagnostics. The development of public-private partnerships and national cancer screening programs is further accelerating testing penetration.

What Is Driving Growth in the HER2 Breast Cancer Tests Market?

Growth in the HER2 breast cancer tests market is driven by several factors including rising global breast cancer incidence, increased use of HER2-targeted therapies, and ongoing improvements in diagnostic precision. Advances in staining reagents, automation systems, and AI-powered pathology tools are making HER2 testing more accurate and scalable.

End-use expansion in oncology hospitals, pathology labs, and companion diagnostics for new HER2-targeted drugs is boosting market relevance. Regulatory approvals for HER2 testing in tumor types beyond breast cancer and increased adoption of multiplex biomarker panels are broadening application scope. As precision medicine becomes central to oncology care, demand for reliable, high-throughput HER2 testing solutions is expected to grow steadily.

SCOPE OF STUDY:

The report analyzes the HER2 Breast Cancer Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Immunohistochemistry Test, Fluorescence / Chromogenic In-Situ Hybridization Test); End-User (Hospitals End-User, Diagnostic Laboratories End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter (Danaher)
  • Becton, Dickinson and Company (BD)
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems (Danaher)
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology (Sysmex)
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics (F. Hoffmann-La Roche)
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics / Biocare Medical
  • Applied Spectral Imaging

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2 Breast Cancer Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Breast Cancer Drives Consistent Demand for HER2 Status Testing in Oncology Diagnostics
    • Increased Adoption of Targeted Therapy Approaches Strengthens Business Case for Routine HER2 Screening
    • Growing Use of HER2 Tests in Treatment Stratification Spurs Integration into First-Line Diagnostic Protocols
    • Expansion of Companion Diagnostics for HER2-Targeted Drugs Throws Spotlight on Precision Testing Technologies
    • Regulatory Approvals for HER2-Positive Therapies Boost Clinical Need for Accurate and Standardized HER2 Testing
    • Adoption of FISH, IHC, and Dual ISH Techniques Enables Multi-Modality Testing Options in Oncology Labs
    • Rising Healthcare Access and Diagnostic Infrastructure in Emerging Markets Enhances HER2 Test Availability
    • Growth in Breast Cancer Screening Programs Supports Early Detection and HER2-Based Prognostic Evaluation
    • Increasing Use of Biopsy and Cytology Samples in HER2 Testing Expands Test Adoption Across Specimen Types
    • Integration of HER2 Testing in Comprehensive Genomic Panels Propels Use in Broader Molecular Oncology Workflows
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2 Breast Cancer Tests Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CHINA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • INDIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030

IV. COMPETITION